MUHAMMAD ZUBAIRI: Open Payments
NPI 1770916355 · EAST HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,704 in 91 payments from 14 companies in 2025. Trend: 2023 $128 · 2024 $572 · 2025 $1,704
Food & beverage: $1,704
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $443 |
| Teva Pharmaceuticals USA, Inc. | 23 | $407 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $204 |
| Ardelyx, Inc. | 5 | $120 |
| Axsome Therapeutics, Inc. | 3 | $91 |
| Neurocrine BioSciences, Inc. | 4 | $89 |
| Novo Nordisk Inc | 4 | $82 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $80 |
| Phathom Pharmaceuticals, Inc. | 7 | $73 |
| Amgen Inc. | 2 | $37 |
Products named: UZEDY, VRAYLAR, CAPLYTA, IBSRELA, UBRELVY, Auvelity, INGREZZA, XIFAXAN.
Industry payments across CT — which companies pay providers there.
